AMPK, AKT, and PDK‐1—the main involved genes in the aforementioned pathway—activate the regulatory proteins responsible for glucose and lipid metabolism and are widely implemented in the treatment of T2DM and NAFLD (Cabrera‐Cruz et al., 2020; El‐Masry et al., 2015; Savova et al., 2023; Zhang et al., 2019). Here, PDK1 is linked to metabolic dysfunction-associated steatotic liver disease.